[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-arteriovenous-malformation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-arteriovenous-malformation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100523693","cera-vascular-plug-system-post-market-clinical-follow-up-100523693",false,"NCT06099015","Cera™ Vascular Plug System Post-Market Clinical Follow-Up","Cera™ Vascular Plug System Post-Market Clinical Follow-Up: A Multi-center, Prospective, Observational, Single-arm, Open-label, Post-market Study","Inclusion Criteria:\n\n1. Aged 18 to 85;\n2. Life expectancy \\> 1 year;\n3. Require arterial or venous embolization in the peripheral vasculature;\n4. Target embolization site(s) allow for safe insertion of the delivery catheter;\n5. Voluntarily sign and date the Informed Consent Form (ICF) prior to any study-related activities commencement;\n6. Willing and able to comply with protocol requirements, including all study visits and procedures.\n7. Patients for whom the doctor has decided to use the Cera Vascular Plug System, regardless of the study.\n\nExclusion Criteria:\n\n1. The subject is pregnant or plan to be pregnant or breast feeding;\n2. The subject has a known allergy or hypersensitivity to any of the device materials including: nickel, stainless steel, polytetrafluoroethylene and titanium nitride;\n3. The subject has a known allergy or hypersensitivity to contrast agent;\n4. The subject has uncorrectable coagulopathy;\n5. The subject has planned use of anticoagulant (e.g. direct thrombin inhibitors, factor Xa inhibitors, vitamin K antagonists) or antiplatelet therapy before, during and\u002For after treatment with the study device, which, in the opinion of the Investigator, would clinically interfere with the study endpoints\n6. The subject has an unresolved systemic infection;\n7. Subject who cannot tolerate general or local anesthesia;\n8. The subject has a connective tissue disorders (e.g. Ehlers-Danlos Syndrome), arteritis (e.g. Takayasu's Disease) or another circulatory disorder;\n9. The subject is participating in other drug or medical device clinical trials;\n10. Any condition (medical or anatomic) making the subject not suitable for transcatheter embolotherapy according to the opinion of the investigator.","ALL","18 Years","85 Years",{"count":20,"type":21},132,"ESTIMATED","OBSERVATIONAL","The objective of the study is to collect and evaluate clinical data on patients of the Lifetech Cera™ Vascular Plug System to:\n\n* confirm the performance\n* confirm the safety\n* identify previously unknown side-effects\n* monitor the identified side-effects (related to the procedures or to the medical devices)\n* identify and analyse emergent risks",[25,26,27,28,29,30],"Aneurysm","Endoleak","Pulmonary Arteriovenous Malformation","Portal Hypertension","Arteriovenous Fistula","Splenic Laceration",[32,33],"Lifetech","Cera Vascular Plug","RECRUITING","2026-06-10",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":38},"2024-06-21",{"date":42,"type":21},"2028-06-30",{"name":44,"class":45},"Lifetech Scientific (Shenzhen) Co., Ltd.","INDUSTRY",9,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100632914","pulmonary-embolism-and-right-to-left-shunts-100632914","NCT07519876","Pulmonary Embolism and Right-to-Left Shunts","PEaRLS","Inclusion Criteria:\n\n1. Age ≥18\n2. Acute pulmonary embolism (any grade\u002Fsize)\n3. Patient or legally authorized representative is able to provide consent to participate in the study\n\nExclusion Criteria:\n\n1. Patients who, in the opinion of the study investigators, are unable to participate in required study activities\n2. Patients unable to undergo MRI imaging",{"count":55,"type":21},256,"Every fetus has a small hole in their heart, called a foramen ovale when they are developing in the womb. For most people this hole closes shortly after birth, but it doesn't close completely in 1 out of every 4 people. This is called a \"patent\" foramen ovale, or PFO. In people with a PFO it is possible for a blood clot in a vein to enter the heart, pass through the opening, and then go into an artery - this is referred to as a paradoxical embolism which passes through a \"Right-to-Left Shunt,\" or RLS. If this occurs, the blood clot can cause a stroke. The most common RLS (more than 90%) is a PFO. Much rarer causes include other types of holes in the heart (like an atrial septal defect, or ASD), or a vascular communication in the lungs (like a pulmonary arteriovenous malformation, or AVM).\n\nWe are investigating whether people with a PE are at higher risk of stroke if they happen to have an RLS compared to PE patients who don't have an RLS. This study will simply observe and compare the differences in stroke-related outcomes between those 2 groups.\n\nParticipation in the study last roughly 90-days and includes the following activities:\n\n* The study team will review your medical records to collect general information such as your age, sex, race\u002Fethnicity, height, weight, medications, medical history, and other medical information\n* Magnetic Resonance Imaging (MRI) of your brain will be done as soon as possible following your enrollment in the study. For more information on MRI scans, please see the \"MRI scan\" section below.\n* A Transcranial Doppler (TCD) with bubble study will be performed to determine if an opening is present in your heart or lungs. TCD is performed using ultrasound. A contrast called agitated saline will be injected into your vein for this test.\n* You will be asked to return for a follow-up visit 90 days after your pulmonary embolism. At this visit, the following will occur:\n\n  1. A second MRI of your brain will be performed.\n  2. You will complete a questionnaire to evaluate whether you may have had a stroke since being discharged from the hospital\n  3. You will meet with a member of the study team who will collect information about your health status.",[58,59,60,61,62,27],"Pulmonary Embolism (PE)","Right-to-Left Shunt","Stroke","Atrial Septal Defects","Patent Foramen Ovale (PFO)",[64,65,59,66,67,60,61,68],"Pulmonary Embolism","PE","PFO","ASD","Patent Foramen Ovale","2026-04-02",{"date":71,"type":38},"2026-04-09",{"date":73,"type":38},"2026-01-30",{"date":75,"type":21},"2028-01",{"name":77,"class":78},"Tufts Medical Center","OTHER",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":79},"100624808","non-invasive-detection-of-pulmonary-right-to-left-shunts-using-the-sonas-ultrasound-device-100624808","NCT07414446","Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device","Novel Approach For The Non-Invasive Detection of Pulmonary Right-to-Left Shunts","SONAS","Inclusion Criteria:\n\n* Age 18 years or older.\n* Suspected or confirmed hereditary hemorrhagic telangiectasia (HHT).\n* Incidentally: Patients who have experienced cryptogenic stroke\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Known or suspected fracture(s) of the temporal \u002F parietal skull bones, or with open skin injuries in the anatomical area of the temporal \u002F parietal lobes.\n* Patients with known metal skull implants in the anatomical area of the temporal \u002F parietal bones, or with anatomical formation of the head or ear tha may interfere with proper headset placement.\n* Patients with known allergies or reactions to parabens, which are present in the gel pad material of the applied part.",{"count":89,"type":21},40,"INTERVENTIONAL",[92],"NA","The goal of this clinical trial is to learn how well the SONAS ultrasound device can detect right-to-left shunts of adults with hereditary hemorrhagic telangiectasia (HHT) who are already scheduled for a contrast bubble echocardiogram (TTCE). The main questions it aims to answer are:\n\n1. How accurately does SONAS detect right-to-left shunts compared to the standard TTCE test?\n2. Can SONAS results help tell the difference between shunts in the heart and shunts in the lungs?\n\nParticipants will wear a headband with the SONAS device on the head while they undergo their routine TTCE bubble test. They will receive the usual contrast (agitated saline) through a vein, and both SONAS and TTCE signals will be recorded at the same time. There will be one examination in rest, and one during a breathing exercise (the Valsalva manoeuvre).",[95,96,27],"Hereditary Haemorrhagic Telangiectasia","PFO - Patent Foramen Ovale",[98,27,59,99,100,101,68,102],"Hereditary Hemorrhagic Telangiectasisa","Contrast Echocardiography","Transcranial Ultrasound","Microbubbles","Cryptogenic Stroke","2026-02-10",{"date":105,"type":38},"2026-02-17",{"date":107,"type":38},"2026-01-07",{"date":109,"type":21},"2026-04-01",{"name":111,"class":78},"St. Antonius Hospital"]